TY - JOUR T1 - Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer JF - Anticancer Research JO - Anticancer Res SP - 4951 LP - 4954 VL - 36 IS - 9 AU - MINEHIKO INOMATA AU - KAZUKI SHIMOKAWA AU - KOTARO TOKUI AU - CHIHIRO TAKA AU - SEISUKE OKAZAWA AU - KENTA KAMBARA AU - TORU YAMADA AU - TOSHIRO MIWA AU - RYUJI HAYASHI AU - TATSUHIKO KASHII AU - SHOKO MATSUI AU - KAZUYUKI TOBE Y1 - 2016/09/01 UR - http://ar.iiarjournals.org/content/36/9/4951.abstract N2 - Aim: We conducted a retrospective study to investigate the frequency of appetite loss during treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in elderly patients, aged 75 years or older, with non-small cell lung cancer harboring EGFR gene mutations. Patients and Methods: Data of a total of 64 patients, including 39 relatively young (hereinafter, younger) patients and 25 elderly patients were analyzed. Results: Appetite loss of all grades (p=0.074) and of grade 3 or greater (p=0.030) was more frequently observed in elderly patients. Diarrhea and oral mucositis were also more frequent in elderly patients, although they did not reach statistical significance. No apparent differences were observed in the frequency of aspartate aminotransferase/ alanine aminotransferase elevation, skin rash or fatigue between the two patient groups. The median (95% confidence interval) progression-free survival times were 10.8 (6.6-16.4) months and 11.8 (4.4-20.3) months in the younger and elderly patient groups, respectively. Conclusion: Our findings suggest that appetite loss is a major adverse effect in elderly patients with non-small cell lung cancer receiving treatment with EGFR-TKIs. ER -